Atlas Trials

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Clinical trial NCT03867370 · TERMINATED

Trial details

NCT number
NCT03867370
Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2019-04-26
Primary completion
2023-08-08
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.